LENZ LENZ Therapeutics Inc.
Price (delayed)
$25.51
Market cap
$702.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
$683.16M
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process
Highlights
The EPS has soared by 93% YoY and by 84% from the previous quarter
The company's net income rose by 29% YoY and by 18% QoQ
LENZ Therapeutics's quick ratio has decreased by 29% from the previous quarter
The equity has declined by 5% since the previous quarter
Key stats
What are the main financial stats of LENZ
Market
Valuations
Earnings
Shares outstanding
27.54M
Market cap
$702.62M
Enterprise value
$683.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$58.61M
Net income
-$49.77M
EBIT
-$49.77M
EBITDA
-$49.71M
Free cash flow
-$59.86M
Per share
Balance sheet
Liquidity
EPS
-$2.34
EPS diluted
-$2.34
Free cash flow per share
-$2.81
Book value per share
$7.42
Revenue per share
$0
TBVPS
$10.12
Total assets
$215.3M
Total liabilities
$11.22M
Debt
$814,000
Equity
$204.08M
Working capital
$201.51M
Debt to equity
0
Current ratio
20.36
Quick ratio
20.1
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.2%
Return on equity
-24.6%
Return on invested capital
-42.3%
Return on capital employed
-24.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LENZ stock price
How has the LENZ Therapeutics stock price performed over time
Intraday
-1.92%
1 week
-2.22%
1 month
16.86%
1 year
21.42%
YTD
-11.64%
QTD
-0.78%
Financial performance
How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.61M
Net income
-$49.77M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 29% YoY and by 18% QoQ
LENZ's operating income is up by 19% year-on-year and by 14% since the previous quarter
Growth
What is LENZ Therapeutics's growth rate over time
Valuation
What is LENZ Therapeutics stock price valuation
P/E
N/A
P/B
3.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 93% YoY and by 84% from the previous quarter
The stock's price to book (P/B) is 40% more than its last 4 quarters average of 2.5
The equity has declined by 5% since the previous quarter
Efficiency
How efficient is LENZ Therapeutics business performance
The return on invested capital has increased by 48% since the previous quarter and by 15% year-on-year
LENZ Therapeutics's ROE has increased by 48% from the previous quarter and by 46% YoY
LENZ's return on assets is up by 32% since the previous quarter and by 23% year-on-year
Dividends
What is LENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LENZ.
Financial health
How did LENZ Therapeutics financials performed over time
LENZ's total liabilities is down by 43% year-on-year but it is up by 29% since the previous quarter
LENZ Therapeutics's quick ratio has decreased by 29% from the previous quarter
LENZ Therapeutics's debt is 100% lower than its equity
LENZ Therapeutics's debt has decreased by 15% QoQ
The equity has declined by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.